

---

## Product Data Sheet

---

Product Name: Eniporide

Cat. No.: GC16924

### Chemical Properties

Cas. No. 176644-21-6

Chemical Name N-(aminoiminomethyl)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)-benzamide

SMILES CC1=C(C(NC(N)=N)=O)C=C(S(C)(=O)=O)C(N2C=CC=C2)=C1

Formula  $C_{14}H_{16}N_4O_3S$  M.Wt 320.4

Solubility  $\leq 5\text{mg/ml}$  in DMSO;  $20\text{mg/ml}$  in dimethyl formamide Storage Store at  $-20^\circ\text{C}$

General tips For obtaining a higher solubility, please warm the tube at  $37^\circ\text{C}$  and shake it in the ultrasonic bath for a while. Stock solution can be stored below  $-20^\circ\text{C}$  for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

### Background

IC50: 4.7 nM

Eniporide is a  $\text{Na}^+/\text{H}^+$  exchange inhibitor.

Regulation of intracellular pH is a very complex process and reflects a net balance of alkalinizing and acidification processes. The  $\text{Na}^+-\text{H}^+$  exchange plays a critical role in the regulation of intracellular pH by removing protons.

In vitro: Eniporide was identified as a selective inhibitor of  $\text{Na}^+-\text{H}^+$  exchange and a compound of the benzoylguanidine group. In addition, eniporide and its metabolite were found to inhibit the  $\text{Na}^+-\text{H}^+$  exchange in acidified rabbit erythrocytes with an IC50 value of  $4.7 \pm 0.6$  and  $15 \pm 3$  nM, respectively [1].

In vivo: Animal study showed that the pretreatment of the mice with the eniporide led to a substantial decrease of annexin-V-positive cardiomyocytes in the I/R 30/90 group from

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

20.2% to 2.2%. Moreover, the pretreatment of I/R 30/90 mice with eniporide resulted in the complete absence of IgG-positive cells, suggesting that the cardiomyocytes with extensive cell membrane leakage were a result of an active cell death program [2].

Clinical trial: Clinical pharmacokinetic-pharmacodynamic evaluation of eniporide with platelet swelling time as a biomarker has been reported. Eniporide showed linear pharmacokinetics with an average half-life of 2 hours. The mean total body clearance and volume of distribution were 34.4 L/h and 77.5 L, respectively. An average of 43% of the dose was recovered unchanged from urine [1].

### References:

- [1] Bhattaram VA, Nagaraja NV, Peters T, Machnig T, Kroesser S, Kovar A, Derendorf H. Population pharmacokinetics of eniporide and its metabolite in healthy subjects and patients with acute myocardial infarction. *J Clin Pharmacol.* 2005 Jun;45(6):631-9.
- [2] Dumont EA et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. *Circulation.* 2000 Sep 26;102(13):1564-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**